Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care.

Unger J, Kushner P, Anderson JE.

Postgrad Med. 2020 Mar 30:1-9. doi: 10.1080/00325481.2020.1744393. [Epub ahead of print]

PMID:
32223687
2.
3.

Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity.

Fanning SW, Hodges-Gallagher L, Myles DC, Sun R, Fowler CE, Plant IN, Green BD, Harmon CL, Greene GL, Kushner PJ.

Nat Commun. 2018 Jun 18;9(1):2368. doi: 10.1038/s41467-018-04413-3.

4.

Quantifying climate feedbacks in polar regions.

Goosse H, Kay JE, Armour KC, Bodas-Salcedo A, Chepfer H, Docquier D, Jonko A, Kushner PJ, Lecomte O, Massonnet F, Park HS, Pithan F, Svensson G, Vancoppenolle M.

Nat Commun. 2018 May 15;9(1):1919. doi: 10.1038/s41467-018-04173-0. Review.

5.

Initiating insulin: How to help people with type 2 diabetes start and continue insulin successfully.

Polonsky WH, Arsenault J, Fisher L, Kushner P, Miller EM, Pearson TL, Tracz M, Harris S, Hermanns N, Scholz BM, Pollom RK, Perez-Nieves M, Pollom RD, Hadjiyianni I.

Int J Clin Pract. 2017 Aug;71(8). doi: 10.1111/ijcp.12973. Epub 2017 Jul 23. No abstract available.

6.

A robust empirical seasonal prediction of winter NAO and surface climate.

Wang L, Ting M, Kushner PJ.

Sci Rep. 2017 Mar 21;7(1):279. doi: 10.1038/s41598-017-00353-y.

7.

Management of Daily Glycemic Fluctuations in Patients With Type 2 Diabetes.

Kushner PR.

J Fam Pract. 2016 Nov;65(11 Suppl). pii: supp_az_1116.

PMID:
28087879
8.

Hypertriglyceridemia: the importance of identifying patients at risk.

Kushner PA, Cobble ME.

Postgrad Med. 2016 Nov;128(8):848-858. Epub 2016 Oct 12. Review.

PMID:
27710158
9.

Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes.

Kushner P.

Womens Health (Lond). 2016 Jun;12(3):379-88. doi: 10.2217/whe-2016-0001. Epub 2016 Feb 29. Review.

10.

User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.

Shaefer CF Jr, Kushner P, Aguilar R.

Postgrad Med. 2015;127(8):818-26. doi: 10.1080/00325481.2015.1090295. Epub 2015 Sep 15. Review.

PMID:
26371721
11.

Recognizing and minimizing hypoglycemia: The need for individualized care.

Lavernia F, Kushner P, Trence D, Rice D, Dailey G, Kuritzky L.

Postgrad Med. 2015;127(8):801-7. doi: 10.1080/00325481.2015.1086628. Epub 2015 Sep 10. Review.

PMID:
26359949
12.

Atmospheric dynamics. Constrained work output of the moist atmospheric heat engine in a warming climate.

Laliberté F, Zika J, Mudryk L, Kushner PJ, Kjellsson J, Döös K.

Science. 2015 Jan 30;347(6221):540-3. doi: 10.1126/science.1257103.

13.

Review of proton pump inhibitors for the initial treatment of heartburn: is there a dose ceiling effect?

Kushner PR, Peura DA.

Adv Ther. 2011 May;28(5):367-88. doi: 10.1007/s12325-011-0013-5. Epub 2011 Apr 6. Review.

PMID:
21484335
14.

Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.

Hollander PA, Kushner P.

Postgrad Med. 2010 May;122(3):71-80. doi: 10.3810/pgm.2010.05.2144.

PMID:
20463416
15.

Patient self-treatment using lansoprazole for frequent nighttime heartburn. Commentary.

Kushner PR.

Postgrad Med. 2010 Jan;122(1):195-7. doi: 10.3810/pgm.2010.01.2114.

PMID:
20107304
16.

Role of the primary care provider in the diagnosis and management of heartburn.

Kushner PR.

Curr Med Res Opin. 2010 Apr;26(4):759-65. doi: 10.1185/03007990903553812. Review.

PMID:
20095795
17.
18.

Short- and long-term management of heartburn and other acid-related disorders: development of an algorithm for primary care providers.

Fennerty MB, Finke KB, Kushner PR, Peura DA, Record L, Riley L, Ruoff GE, Simonson W, Wright WL.

J Fam Pract. 2009 Jul;58(7 Suppl Short):S1-12. No abstract available.

PMID:
19825313
19.

Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies.

Kushner PR, Snoddy AM, Gilderman L, Peura DA.

Postgrad Med. 2009 Jul;121(4):67-75. doi: 10.3810/pgm.2009.07.2019.

PMID:
19641272
20.
21.

Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells.

Hodges-Gallagher L, Valentine CD, El Bader S, Kushner PJ.

Breast Cancer Res Treat. 2008 May;109(2):241-50. Epub 2007 Jul 19.

PMID:
17638070
22.

Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.

Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID.

J Cell Biochem. 2008 Feb 1;103(2):624-35.

PMID:
17562544
23.

Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.

Hodges-Gallagher L, Valentine CD, Bader SE, Kushner PJ.

Breast Cancer Res Treat. 2007 Nov;105(3):297-309. Epub 2006 Dec 21.

PMID:
17186358
24.

Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes.

Hinnen D, Nielsen LL, Waninger A, Kushner P.

J Am Board Fam Med. 2006 Nov-Dec;19(6):612-20. Erratum in: J Am Board Fam Med. 2007 Mar-Apr;20(2):240.

25.

p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1.

Frigo DE, Basu A, Nierth-Simpson EN, Weldon CB, Dugan CM, Elliott S, Collins-Burow BM, Salvo VA, Zhu Y, Melnik LI, Lopez GN, Kushner PJ, Curiel TJ, Rowan BG, McLachlan JA, Burow ME.

Mol Endocrinol. 2006 May;20(5):971-83. Epub 2006 Jan 12.

PMID:
16410316
26.

Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.

Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y, Lisanti MP, Albanese C, Katzenellenbogen BS, Kushner PJ, Weber B, Rosen EM, Pestell RG.

Cancer Res. 2005 Aug 1;65(15):6557-67.

27.
28.

ERbeta Binds N-CoR in the Presence of Estrogens via an LXXLL-like Motif in the N-CoR C-terminus.

Webb P, Valentine C, Nguyen P, Price RH Jr, Marimuthu A, West BL, Baxter JD, Kushner PJ.

Nucl Recept. 2003 Jun 28;1(1):4.

29.

Design of thyroid hormone receptor antagonists from first principles.

Webb P, Nguyen NH, Chiellini G, Yoshihara HA, Cunha Lima ST, Apriletti JW, Ribeiro RC, Marimuthu A, West BL, Goede P, Mellstrom K, Nilsson S, Kushner PJ, Fletterick RJ, Scanlan TS, Baxter JD.

J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):59-73. Review.

PMID:
12650702
30.

Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.

Webb P, Nguyen P, Kushner PJ.

J Biol Chem. 2003 Feb 28;278(9):6912-20. Epub 2002 Dec 13.

31.

Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression.

Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price RH Jr, Pestell RG, Kushner PJ.

J Biol Chem. 2002 Jul 5;277(27):24353-60. Epub 2002 May 1.

32.

Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist.

Baxter JD, Goede P, Apriletti JW, West BL, Feng W, Mellstrom K, Fletterick RJ, Wagner RL, Kushner PJ, Ribeiro RC, Webb P, Scanlan TS, Nilsson S.

Endocrinology. 2002 Feb;143(2):517-24.

PMID:
11796506
33.

p300 Modulates the BRCA1 inhibition of estrogen receptor activity.

Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM.

Cancer Res. 2002 Jan 1;62(1):141-51.

34.

A splice variant of estrogen receptor beta missing exon 3 displays altered subnuclear localization and capacity for transcriptional activation.

Price RH Jr, Butler CA, Webb P, Uht R, Kushner P, Handa RJ.

Endocrinology. 2001 May;142(5):2039-49.

PMID:
11316771
35.

Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity.

Lopez GN, Turck CW, Schaufele F, Stallcup MR, Kushner PJ.

J Biol Chem. 2001 Jun 22;276(25):22177-82. Epub 2001 Apr 11.

36.

Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity.

Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S, Hopp T, Fuqua SA, Lopez GN, Kushner PJ, Pestell RG.

J Biol Chem. 2001 May 25;276(21):18375-83. Epub 2001 Mar 9.

37.

Role of direct interaction in BRCA1 inhibition of estrogen receptor activity.

Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ, Pestell RG, Rosen EM.

Oncogene. 2001 Jan 4;20(1):77-87.

38.

Estrogen receptor pathways to AP-1.

Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P.

J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):311-7. Review.

PMID:
11162939
39.

Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway.

Feng W, Webb P, Nguyen P, Liu X, Li J, Karin M, Kushner PJ.

Mol Endocrinol. 2001 Jan;15(1):32-45.

PMID:
11145737
40.

The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs).

Webb P, Anderson CM, Valentine C, Nguyen P, Marimuthu A, West BL, Baxter JD, Kushner PJ.

Mol Endocrinol. 2000 Dec;14(12):1976-85.

PMID:
11117528
41.

An antiestrogen-responsive estrogen receptor-alpha mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen.

Webb P, Nguyen P, Valentine C, Weatherman RV, Scanlan TS, Kushner PJ.

J Biol Chem. 2000 Dec 1;275(48):37552-8.

42.

Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding.

Pissios P, Tzameli I, Kushner P, Moore DD.

Mol Cell. 2000 Aug;6(2):245-53.

43.

Oestrogen receptor function at classical and alternative response elements.

Kushner PJ, Agard D, Feng WJ, Lopez G, Schiau A, Uht R, Webb P, Greene G.

Novartis Found Symp. 2000;230:20-6; discussion 27-40. Review.

PMID:
10965500
44.

Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators.

An J, Ribeiro RC, Webb P, Gustafsson JA, Kushner PJ, Baxter JD, Leitman DC.

Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15161-6.

45.

The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions.

Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S, Kushner PJ.

Mol Endocrinol. 1999 Oct;13(10):1672-85.

PMID:
10517669
46.

Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins.

Ma H, Hong H, Huang SM, Irvine RA, Webb P, Kushner PJ, Coetzee GA, Stallcup MR.

Mol Cell Biol. 1999 Sep;19(9):6164-73.

47.

Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators.

Lopez GN, Webb P, Shinsako JH, Baxter JD, Greene GL, Kushner PJ.

Mol Endocrinol. 1999 Jun;13(6):897-909.

PMID:
10379889
48.

Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.

Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC.

Clin Cancer Res. 1999 Feb;5(2):251-6.

49.

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL.

Cell. 1998 Dec 23;95(7):927-37.

50.

Molecular and structural biology of thyroid hormone receptors.

Apriletti JW, Ribeiro RC, Wagner RL, Feng W, Webb P, Kushner PJ, West BL, Nilsson S, Scanlan TS, Fletterick RJ, Baxter JD.

Clin Exp Pharmacol Physiol Suppl. 1998 Nov;25:S2-11. Review.

PMID:
9809185

Supplemental Content

Loading ...
Support Center